How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,947 results for

Desquamation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Odontogenic keratocyst: imaging features of a benign lesion with an aggressive behaviour (PubMed)

and are characterised by a cystic space containing desquamated keratin with a uniform lining of parakeratinised squamous epithelium. The reported age distribution of OKCs is considerably wide, with a peak of incidence in the third decade of life and a slight male predominance. OKCs originate in tooth-bearing regions and the mandible is more often affected than the maxilla. In the mandible, the most common location is the posterior sextant, the angle or the ramus. Conversely, the anterior sextant and the third molar

Full Text available with Trip Pro

2018 Insights into imaging

162. The Periodontium as a Potential Cause of Orofacial Pain: A Comprehensive Review (PubMed)

of these pathologies conducted in the MEDLINE/PubMed Database. Acute infectious entities such as gingival and periodontal abscesses are emergencies that require a rapid response. Periodontitis associated with endodontic processes, necrotizing periodontal disorders, desquamative gingivitis, gingival recession, and mucogingival herpetic lesions, cause mild to severe pain due to tissue destruction and loss. Other lesions that lead to periodontal discomfort include gingival enlargement and periodontal ligament strains

Full Text available with Trip Pro

2018 The open dentistry journal

163. Diffuse erythematous rash resistant to treatment. (PubMed)

Diffuse erythematous rash resistant to treatment. A 39-year-old woman presented to the emergency department for evaluation of diffuse redness, itching, and tenderness of her skin. The patient said the eruption began 4 months earlier as localized plaques on her scalp, elbows, and beneath both breasts. Over the course of a few days, the redness became more diffuse, affecting most of her body. She also noticed swelling and skin desquamation on her lower extremities. WHAT IS YOUR DIAGNOSIS? HOW

2018 Journal of Family Practice

164. Prophylactically applied Hydrofilm polyurethane film dressings reduce radiation dermatitis in adjuvant radiation therapy of breast cancer patients. (PubMed)

compartments, with an overall response rate of 89.3%. Hydrofilm completely prevented moist desquamation and significantly reduced patients' subjective experience of itching and pain.The obtained results along with a favorable cost-benefit ratio and an easy and quick application suggest a prophylactic application of Hydrofilm in adjuvant radiotherapy of breast cancer patients to reduce or even prevent radiation dermatitis.

2018 Acta Oncologica

165. Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. (PubMed)

with PBC; hand-foot skin reaction, rash/desquamation, mucositis, and vascular events were more frequent with NPBC.MITO-8 QoL analysis shows that deterioration of some functioning and symptom scales is lower with PBC, with improvement of emotional functioning and pain, despite worsening of toxicity-related items.NCT00657878.

2018 Annals of Oncology

166. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. (PubMed)

postsurgical wounds, postpartum, postabortion, burns, soft tissue injuries, pharyngitis, and focal infections. Symptoms are due to toxin production and infection focus. Early symptoms include fever, chills, malaise, rash, vomiting, diarrhea, and hypotension. Diffuse erythema and desquamation may occur later in the disease course. Laboratory assessment may demonstrate anemia, thrombocytopenia, elevated liver enzymes, and abnormal coagulation studies. Diagnostic criteria are available to facilitate

2018 Journal of Emergency Medicine

167. Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants

months ] Skin involvement under abatacept therapy as assessed by Psoriasis Area and Severity Index (PASI) [ Time Frame: 12 months ] The PASI score consists of 4 items that are assessed (surface area, severity of erythema [redness], induration [thickness], and desquamation [scale]), evaluated for 4 body areas (head, trunk, and upper and lower extremities). Physician Global Assessment (PGA) [ Time Frame: 12 months ] Number of reasons for stopping or switching therapy [ Time Frame: 12 months ] Including

2018 Clinical Trials

168. Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)

, colorectal cancer, bronchial cancer). Although having a much better tolerance profile than the "classical" cytotoxic treatments used in the same indications, these treatments, however, have frequent cutaneous toxicities that are inconvenient for patients. According to the molecules, they can affect 80 to 90% of patients treated from the first weeks of treatment and to different degrees. They appear as well in the skin (acneiform rash, erythema, desquamation, xerosis, pruritus) as skin appendages

2018 Clinical Trials

169. Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

% of area involved, 1=<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%.) Within each area, the severity of disease is based on 3 clinical signs: erythema or redness, induration or thickness, and desquamation or scaliness. Each is graded on a scale from 0(none) to 4(maximum.) The sum of all 3 parameters is calculated for each body section, multiplied by the area score for that section and then multiplied by the weight of that section (.1for head, .2 arms, .3 trunk and .4 legs) Secondary Outcome (...) . It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.) Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16 [ Time Frame: 4 weeks, 12 weeks, 16 weeks ] The Investigator will rate the severity of of disease based on the assessment of 3 clinical signs (erythema, induration, desquamation) wherein 0=no signs of psoriasis, 1=almost clear, 2=mild

2018 Clinical Trials

170. StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients

for application during the treatment and 4 weeks further after the treatment ends. Outcome Measures Go to Primary Outcome Measures : grade 2 acute radiation dermatitis [ Time Frame: 10 weeks ] when patient develops grade 2 acute radiation dermatitis as scored by Common Terminology Criteria for Adverse Event (CTCAE) version 4.03 scale with grade 1 the mildest, Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema; patchy moist desquamation; moderate edema Grade 3: moist desquamation

2018 Clinical Trials

171. Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

itching) Secondary Outcome Measures : Change in Investigator Global Assessment (IGA) from baseline [ Time Frame: week 8 ] 5-point scale used to assess the overall severity of psoriasis by evaluting induration, erythema and desquamation (0=clear to 4=severe) Change in Psoriasis Area Severity Index (PASI) from baseline [ Time Frame: week 8 ] A quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance (0 = no disease to 72 = maximum disease

2018 Clinical Trials

172. Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

% of involved area 30-49% of involved area 50-69% of involved area 70-89% of involved area 90-100% of involved area Within each area, the severity is estimated by three clinical signs: erythema, induration and desquamation. Maastricht Ankylosing Spondylitis Enthesitis Score [ Time Frame: 1, 3 and 6 months ] The Maastricht Ankylosing Spondylitis Enthesitis Score uses 13 most specific and sensitive sites. These include the bilateral first and seventh costochondral joints, the anterior and posterior superior

2018 Clinical Trials

173. Kawasaki Disease in the neonate: case report and literature review. (PubMed)

-pitting edema and erythema of his feet, and arthritis. His full septic work-up and viral studies were negative. On Day 7 he was treated with intravenous immunoglobulin, and over the next 48 h his symptoms including extremity edema resolved, he no longer required supplemental oxygen, and fever did not recur. On day 9 of illness he had marked thrombocytosis. Subsequently, he developed distal extremity desquamation. Repeated echocardiograms excluded the presence of coronary artery aneurysms (CAA).We

Full Text available with Trip Pro

2018 Pediatric Rheumatology

174. RS3PE syndrome developing during the course of probable toxic shock syndrome: a case report. (PubMed)

department with a rash that had appeared 2 days earlier and a fever that had developed on the day of his visit. Based on clinical findings of fever, erythema exudativum multiforme, transitory hypotension, conjunctiva hyperemia, elevated creatine kinase, and desquamation, we suspected toxic shock syndrome (TSS). Therefore, we started treatment with vancomycin (1 g/day) and clindamycin (600 mg/day), after which his fever rapidly remitted. However, pitting edema on the dorsum of his hands and feet appeared

Full Text available with Trip Pro

2018 BMC Infectious Diseases

175. Midostaurin (Rydapt) for acute myeloid leukaemia

one adverse event (AE) of any grade; grade =3 AEs were reported in all but one patient in the safety set. Events tended to occur in the induction and consolidation phases, and less frequently reported during maintenance. 6 These grade =3 AEs were reported in similar proportions of patients in each treatment group with the exception of rash / desquamation, occurring in 14% of midostaurin patients and in 7.6% of placebo patients. 8 The most common grade =3 AEs were haematological; thrombocytopenia

2018 Scottish Medicines Consortium

176. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. (PubMed)

, desquamation, and induration, and by body regions head, upper limbs, trunk, and lower limbs), absence of skin-related quality-of-life impact (Dermatology Life Quality Index [DLQI] = 0), "complete disease control" (patient's global assessment [PtGA] = 0), and adverse events.After adjustment, baseline characteristics were balanced among study groups (adalimumab = 875 vs. placebo = 427; etanercept = 260 vs. placebo = 130). Compared with etanercept, adalimumab was associated with significantly better placebo

2018 Value in Health

177. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. (PubMed)

levels, with a 30% targeted rate of dose-limiting toxicity (DLT) measured during the 6 weeks of treatment plus 4 weeks of follow-up. DLTs were defined as confluent moist desquamation > 100 cm2, nonhematologic toxicity grade ≥ 3, toxicity that requires an RT dose delay > 1 week, absolute neutrophil count < 1,000/mm3, platelet count < 50,000/mm3, or hemoglobin < 8.0 g/dL if possibly, probably, or definitely related to study treatment. Results Five DLTs occurred: Four were moist desquamation (two each

2018 Journal of Clinical Oncology

178. Skin acceptability of a cosmetic moisturizer formulation in female subjects with sensitive skin (PubMed)

of moisturizer application (appearance of erythema, formation of edema, and skin desquamation; scored according to an adapted Draize and Kligman scale). Only subjects with a treatment compliance of ≥80% were included in the final analysis.In total, 35 subjects initiated and completed the study; all were compliant to the minimum study product usage. Per investigator clinical dermatological assessment at study end, none of the 35 subjects had skin reactions in the area of moisturizer application and there were

Full Text available with Trip Pro

2018 Clinical, cosmetic and investigational dermatology

179. Endobronchial biopsy in the final diagnosis of chronic obstructive pulmonary disease and asthma: a clinicopathological study (PubMed)

. There were no significant differences in epithelial desquamation or metaplasia, mucosal or submucosal inflammation, the presence of eosinophils, submucosal glandular hyperplasia or submucosal smooth muscle hyperplasia between groups.The thickness of the RBM is the only reproducible histopathological feature to differentiate COPD from irreversible asthma.The study included a limited number of patients. A qualitative approach was used to compare epithelial cell injury, inflammation, submucosal glandular

Full Text available with Trip Pro

2018 Annals of Saudi Medicine

180. An extremely rare case of hand prolapse with preterm premature rupture in the membrane of one twin (PubMed)

of time of 23 days until delivery. Daily dressing by applying collagen to dry skin and silicone to keep moisture was done to the protruding hand to prevent dehydration and desquamation of the skin. Prophylactic antibiotics were used and the patient underwent emergent cesarean section due to uncontrolled preterm labor at 25.2 weeks. To the best of our knowledge, this is the first case of hand prolapse of one twin with extended period of latency before delivery.

Full Text available with Trip Pro

2018 Obstetrics & gynecology science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>